GLPG3067 + GLPG2222 + GLPG2737

GLPG3067 + GLPG2222 + GLPG2737 is an investigational oral triple combination therapy developed for the treatment of cystic fibrosis (CF). All three components are small molecule CFTR modulators, each targeting different aspects of the defective cystic fibrosis transmembrane conductance regulator (CFTR) protein caused by mutations such as F508del. - **GLPG2222** acts as a type I corrector, improving folding and trafficking of mutant CFTR to the cell surface. - **GLPG3067** is a potentiator that increases the open probability of CFTR channels at the cell membrane. - **GLPG2737** is a novel type II corrector (C2 corrector), which further enhances proper folding and stability of CFTR when used in combination with other modulators[4][7][8]. The triple combination aims to maximize restoration of functional CFTR protein at the epithelial surface, thereby improving chloride transport and clinical outcomes in patients with cystic fibrosis, particularly those homozygous or heterozygous for F508del mutations[3][6][8]. The regimen has been evaluated in Phase 1 and Phase 2 clinical trials for safety, tolerability, pharmacokinetics, and efficacy endpoints such as sweat chloride reduction and lung function improvement[1][3][5].